Avinger Inc Form 8-K May 20, 2015

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 20, 2015

AVINGER, INC.

(Exact name of Registrant as specified in its charter)

**Delaware** (State or other jurisdiction of

incorporation or organization)

**0001-36817** (Commission

File Number)

**20-8873453** (I.R.S. Employer

Identification Number)

400 Chesapeake Drive

## Edgar Filing: Avinger Inc - Form 8-K

### Redwood City, California 94063


(Address of principal executive office) (Zip Code)

(	650	241 (	-790	0

(Registrant s telephone number, including area code)

#### N/A

(Former Name or Former Address, if Changed Since Last Report)



- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: Avinger Inc - Form 8-K

Item 8.01.	Other Events.
	ress release entitled Avinger Announces 30-Day VISION Trial Results at EuroPCR 2015 which contained ISION clinical study. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein
	corporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange tas shall be expressly set forth by specific reference in such a filing.
Item 9.01.	Financial Statements and Exhibits.

Exhibit No. Description

Exhibits.

99.1

Press release dated as of May 20, 2015, entitled Avinger Announces 30-Day VISION Trial Results at EuroPCR 2015.

2

# Edgar Filing: Avinger Inc - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AVINGER, INC.

Date: May 20, 2015 By: /s/ Jeffrey M. Soinski Jeffrey M. Soinski

Chief Executive Officer

3